Clinical Study

Mild to moderate Alzheimer's Disease (IV-2)

The Butler Hospital Memory & Aging Program is conducting a clinical research study of an Intravenous Immunoglobulin (IV-2) treatment. This study tests whether the investigational drug IV-2 safely slows the rate of decline of dementia symptoms in patients with mild to moderate
Alzheimer’s Disease (AD).

Qualified participants must be:

•  from 55 to 85 years of age
•  diagnosed with mild to moderate Alzheimer's disease
•  not taking Coumadin®
•  accompanied by a regular caregiver to 9 office visits, plus 36 infusions, which may take place at home after initial infusions, over a 1.5-year period

For more information please call 401-455-6403.

All inquiries are confidential.